An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4 diarrhea for up to 3 days or persistent Grade 2 diarrhea for more than 5 days after treatment with Yervoy and/or Opdivo
Renal Cell Carcinoma|Melanoma|Lung Cancer
DRUG: Infliximab + Prednisone|DRUG: Methylprednisolone + Prednisone
Improvement in management of immune related grade 3 and 4 diarrhea as measured by proportion of responders to less than or equal to grade 1, Up to 78 hours|Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1, Up to 78 hours
Number of days to improvement to less than grade 1 diarrhea, Randomization up to 12 weeks|Quality of life as measured by European Quality of Life-5 Dimensions Questionnaire (EQ-5D), Up to 12 weeks|Number of hospitalizations, Up to 12 weeks|Duration of hospitalizations, Up to 12 weeks|Number of patients with adverse events (AEs), Up to 12 weeks|Number of patients with AEs related to steroid use, Up to 12 weeks|Number of patients with Gastrointestinal (GI) specific AEs, Up to 12 weeks
The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4 diarrhea for up to 3 days or persistent Grade 2 diarrhea for more than 5 days after treatment with Yervoy and/or Opdivo